Covid-19

DefinitionNLM MeSH D000086382

A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. A coronavirus, SARS-CoV-2 VIRUS, in the genus BETACORONAVIRUS is the causative agent.

Source: U.S. National Library of Medicine — MeSH (COVID-19)

Drugs reporting Covid-19 (182)

Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.

1. 1Nirmatrelvir22,79843%
2. 2Manganese Sulfate2329%
3. 3Tetrahydrozoline8225%
4. 4Ritonavir22,99424%
5. 5Estriol36322%
6. 6Ocrelizumab11,55419%
7. 7Opium217%
8. 8Mavorixafor117%
9. 9Phenoxybenzamine415%
10. 10Chlorcyclizine415%
11. 11Coenzyme A114%
12. 12Diethyl Oxalacetate114%
13. 13Malic Acid213%
14. 14Glyphosate212%
15. 15Acetaldehyde211%
16. 16Immunoglobulin G2,14911%
17. 17Molnupiravir4819.3%
18. 18Bacillus Subtilis48.5%
19. 19Manganese328.4%
20. 20Xylometazoline448.3%
21. 21Velaglucerase Alfa1678.2%
22. 22Mosunetuzumab678.1%
23. 23Elapegademase227.5%
24. 24Cobalt37.5%
25. 25Racepinephrine37.3%
26. 26Remdesivir9076.9%
27. 27Obinutuzumab1,0766.8%
28. 28Pexidartinib446.3%
29. 29Crovalimab56.2%
30. 30Curcumin75.9%
31. 31Zinc Picolinate75.9%
32. 32Apple Cider Vinegar75.9%
33. 33Cider Vinegar75.9%
34. 34Rna15.9%
35. 35Polatuzumab Vedotin5215.7%
36. 36Apple Cider75.7%
37. 37Inebilizumab295.6%
38. 38Pemivibart25.6%
39. 39Isatuximab2895.5%
40. 40Golodirsen235.4%
41. 41Sinusitisinum35.4%
42. 42Idursulfase2065.3%
43. 43Taliglucerase Alfa295.2%
44. 44Protriptyline55.2%
45. 45Factor Viia45.1%
46. 46Glofitamab1035.0%
47. 47Felodipine5525.0%
48. 48Fosfomycin284.9%
49. 49Saccharomyces Cerevisiae384.8%
50. 50Baricitinib4474.8%
51. 51Ofatumumab1,5154.7%
52. 52Tazemetostat724.6%
53. 53Quercetin544.6%
54. 54Brodalumab874.5%
55. 55Efgartigimod Alfa1784.4%
56. 56Capsicum Oleoresin14.3%
57. 57Bendamustine1,1364.2%
58. 58Icatibant3534.2%
59. 59Siponimod3654.1%
60. 60Upadacitinib3,1754.1%
61. 61Satralizumab644.1%
62. 62Caffeic Acid24.1%
63. 63Ponesimod134.0%
64. 64Epcoritamab474.0%
65. 65Zinc Chloride9574.0%
66. 66Danicopan93.9%
67. 67Eteplirsen853.9%
68. 68Mitapivat283.9%
69. 69Viltolarsen63.9%
70. 70Clemastine513.9%
71. 71Zinc Gluconate9873.8%
72. 72Mineral Oil1213.8%
73. 73Teclistamab733.7%
74. 74Casimersen313.7%
75. 75Loncastuximab Tesirine133.7%
76. 76Hippurate423.7%
77. 77Osilodrostat713.6%
78. 78Pegcetacoplan603.6%
79. 79Phendimetrazine23.5%
80. 80Lanadelumab1033.5%
81. 81Tafasitamab303.5%
82. 82Naphazoline783.4%
83. 83Rilonacept333.4%
84. 84Sutimlimab93.4%
85. 85Zilucoplan233.4%
86. 86Dotatate1963.4%
87. 87Mycophenolic Acid1,0373.3%
88. 88Nefazodone43.3%
89. 89Belatacept1483.2%
90. 90Migalastat173.2%
91. 91Zinc Acetate613.2%
92. 92Potassium Bicarbonate223.2%
93. 93Zanubrutinib1213.2%
94. 94Doconexent43.1%
95. 95Zinc1,1993.1%
96. 96Cefixime883.0%
97. 97Diroximel Fumarate3493.0%
98. 98Pirtobrutinib213.0%
99. 99Anifrolumab493.0%
100. 100Benzethonium63.0%
101. 101Avacopan1693.0%
102. 102Levalbuterol1912.9%
103. 103Risankizumab2,2342.9%
104. 104Linagliptin6092.9%
105. 105Canakinumab3102.9%
106. 106Burosumab1782.9%
107. 107Voclosporin2442.9%
108. 108Plecanatide542.8%
109. 109Calcifediol632.8%
110. 110Eliglustat422.8%
111. 111Doxylamine2112.8%
112. 112Azelastine5872.8%
113. 113Venetoclax1,6402.8%
114. 114Ubrogepant1532.7%
115. 115Givosiran372.7%
116. 116Revefenacin202.7%
117. 117Olipudase Alfa32.7%
118. 118Retifanlimab12.7%
119. 119Risdiplam1072.7%
120. 120Vitamin D362.7%
121. 121Epinephrine2,9372.7%
122. 122Menthol1,4202.7%
123. 123Atrasentan22.7%
124. 124Belumosudil792.7%
125. 125Flotufolastat12.6%
126. 126Mycophenolate3,4662.6%
127. 127Mycophenolate Mofetil3,4662.6%
128. 128Pyridostigmine2692.6%
129. 129Tacrolimus3,9272.6%
130. 130Rezafungin22.6%
131. 131Halobetasol382.6%
132. 132Ixekizumab9202.5%
133. 133C1 Esterase Inhibitor1492.5%
134. 134Solriamfetol922.5%
135. 135Prilocaine432.4%
136. 136Apixaban1,5662.4%
137. 137Vadadustat62.4%
138. 138Benralizumab4542.4%
139. 139Palivizumab3632.4%
140. 140Avalglucosidase Alfa202.4%
141. 141Daratumumab9722.4%
142. 142Maribavir552.4%
143. 143Omaveloxolone362.3%
144. 144Potassium Bitartrate42.3%
145. 145Elranatamab202.3%
146. 146Telisotuzumab12.2%
147. 147Deferiprone652.2%
148. 148Ibrutinib1,7302.2%
149. 149Dasiglucagon12.2%
150. 150Levocarnitine762.2%
151. 151Ixazomib6072.1%
152. 152Cladribine1972.1%
153. 153Triheptanoin112.1%
154. 154Lemborexant542.1%
155. 155Acalabrutinib2402.1%
156. 156Atogepant1282.1%
157. 157Ravulizumab2502.0%
158. 158Cerliponase102.0%
159. 159Ublituximab712.0%
160. 160Leniolisib141.9%
161. 161Lutetium3381.9%
162. 162Ciltacabtagene Autoleucel961.9%
163. 163Pomalidomide1,8281.8%
164. 164Eptinezumab1531.8%
165. 165Fostamatinib1161.8%
166. 166Carfilzomib4871.8%
167. 167Olodaterol901.7%
168. 168Elosulfase Alfa911.7%
169. 169Rimegepant2111.7%
170. 170Ozanimod1321.6%
171. 171Galsulfase591.6%
172. 172Nusinersen1141.5%
173. 173Lasmiditan171.5%
174. 174Alectinib1041.5%
175. 175Deucravacitinib361.3%
176. 176Tetraxetan1421.2%
177. 177Vipivotide Tetraxetan1421.2%
178. 178Ritlecitinib201.1%
179. 179Ganaxolone61.0%
180. 180Berotralstat35—
181. 181Beta Carotene3—
182. 182Benzene1—

Related reactions

Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.

• Illness37 shared · 0.18
• Product Dose Omission Issue81 shared · 0.15
• Urinary Tract Infection37 shared · 0.13
• Pneumonia102 shared · 0.12
• Nasopharyngitis29 shared · 0.11
• Cough61 shared · 0.11
• Inappropriate Schedule Of Product Administration30 shared · 0.11
• Infection28 shared · 0.10
• Influenza21 shared · 0.10
• Pyrexia91 shared · 0.09

Literature

Recent PubMed references pinned to COVID-19 as a MeSH major topic. About the reaction term itself — not about any specific drug.

• Symptoms, mechanisms, and management of long COVID: understanding its prevalence, characteristics, and healthcare challenges in Saudi Arabia.
  Frontiers in cellular and infection microbiology · 2026 · Albelasi A
  PMID 42205482DOI 10.3389/fcimb.2026.1747443
• "If that goes away, the house of cards falls": challenges and solutions to ensuring CHW sustainability.
  Frontiers in public health · 2026 · Wilkinson-Lee AM, Hunter DR, Stalker KC, et al.
  PMID 42205438DOI 10.3389/fpubh.2026.1747834
• Parental Perceptions and Concerns Regarding Infection Control in a Pediatric Dental Setting Post Covid-19 Pandemic in Saudi Arabia: A Cross-Sectional Study.
  Oral health & preventive dentistry · 2026 · Almulhim B
  PMID 42205104DOI 10.3290/j.ohpd.c_2693
• DAMP Laden Extracellular Vesicles From the Airways of Patients With Severe SARS-CoV-2 Respiratory Infection Compromise Inflammation and Cellular Metabolism.
  Journal of extracellular vesicles · 2026 · Rees A, Richards O, Raikes ME, et al.
  PMID 42204964DOI 10.1002/jev2.70288
• Turkish pregnant women's opinions, beliefs, and attitudes about maternal tetanus, diphtheria, and pertussis, influenza, coronavirus disease 2019, and respiratory syncytial virus vaccines.
  Journal of tropical pediatrics · 2026 · Ağralı-Eröz N, Karadağ-Öncel E, Gülşah-Şahingöz A, et al.
  PMID 42204809DOI 10.1093/tropej/fmag032
• Long-term cognitive outcomes after mild COVID-19, critical COVID-19, and non-COVID critical illness: a prospective cohort comparison.
  Scientific reports · 2026 · Raeder V, Quitschau A, Gorsler A, et al.
  PMID 42204241DOI 10.1038/s41598-026-54890-6